Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 46


Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.

Zorman JK, Esser M, Raedler M, Kreiswirth BN, Ala'Aldeen DA, Kartsonis N, Smugar SS, Anderson AS, McNeely T, Arduino JM.

Hum Vaccin Immunother. 2013 Sep;9(9):1857-64. doi: 10.4161/hv.25253. Epub 2013 Jun 18.


Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.

Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A.

JAMA. 2013 Apr 3;309(13):1368-78. doi: 10.1001/jama.2013.3010.


The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, Gates DF Jr, Kuo WL, Smugar SS, Reiss TF, Barnes N, Fuhlbrigge A, Milgrom H, Schatz M, Knorr B.

J Allergy Clin Immunol. 2012 Nov;130(5):1071-1077.e10. doi: 10.1016/j.jaci.2012.07.057. Epub 2012 Oct 1.


Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study.

Seymour MW, Kelly S, Beals CR, Malice MP, Bolognese JA, Dardzinski BJ, Cheng AS, Cummings CE, Smugar SS, McClinton C, Fox A, Dooley WM, Pitzalis C, Taylor PC.

Arthritis Res Ther. 2012 Sep 12;14(5):R198. doi: 10.1186/ar4034.


Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.

Moustafa M, Aronoff GR, Chandran C, Hartzel JS, Smugar SS, Galphin CM, Mailloux LU, Brown E, Dinubile MJ, Kartsonis NA, Guris D.

Clin Vaccine Immunol. 2012 Sep;19(9):1509-16. doi: 10.1128/CVI.00034-12. Epub 2012 Jul 25.


Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale.

Gammaitoni AR, Smugar SS, Jensen MP, Galer BS, Bolognese JA, Alon A, Hewitt DJ.

Pain Med. 2013 Apr;14(4):526-32. doi: 10.1111/j.1526-4637.2012.01423.x. Epub 2012 Jul 3.


The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients.

Adachi M, Taniguchi H, Tohda Y, Sano Y, Ishine T, Smugar SS, Hisada S.

J Asthma. 2012 Aug;49(6):649-56. doi: 10.3109/02770903.2012.690479. Epub 2012 Jun 28.


Airway obstruction lability helps distinguish levels of disease activity in asthma.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen LM, Smugar SS, Noonan G, Reiss TF, Knorr BA.

Respir Med. 2012 Apr;106(4):500-7. doi: 10.1016/j.rmed.2011.12.013. Epub 2012 Jan 31.


Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast.

Wasfi YS, Kemp JP, Villarán C, Massaad R, Xin W, Smugar SS, Knorr BA, Philip G.

Allergy Asthma Proc. 2011 Nov-Dec;32(6):453-9. doi: 10.2500/aap.2011.32.3482.


The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.

Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA.

Vaccine. 2012 Feb 21;30(9):1729-36. doi: 10.1016/j.vaccine.2011.12.045. Epub 2011 Dec 20.


The pain quality response profile of pregabalin in the treatment of neuropathic pain.

Jensen MP, Gammaitoni AR, Bolognese JA, Alon A, Smugar SS, Galer BS, Hewitt DJ.

Clin J Pain. 2012 Oct;28(8):683-6. doi: 10.1097/AJP.0b013e31823f9e64.


Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications.

Nelsen LM, Shields KE, Cunningham ML, Stoler JM, Bamshad MJ, Eng PM, Smugar SS, Gould AL, Philip G.

J Allergy Clin Immunol. 2012 Jan;129(1):251-4.e1-6. doi: 10.1016/j.jaci.2011.09.003. Epub 2011 Oct 13. No abstract available.


The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.

Wasfi YS, Villarán C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, Knorr BA.

Respir Med. 2012 Jan;106(1):34-46. doi: 10.1016/j.rmed.2011.08.019. Epub 2011 Sep 25.


Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.

Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP.

Cardiovasc Ther. 2012 Dec;30(6):342-50. doi: 10.1111/j.1755-5922.2011.00283.x. Epub 2011 May 25.


Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.

Peloso PM, Gammaitoni A, Smugar SS, Wang H, Moore AR.

BMC Musculoskelet Disord. 2011 Jul 18;12:165. doi: 10.1186/1471-2474-12-165.


Sensitivity of single-domain versus multiple-domain outcome measures to identify responders in chronic low-back pain: pooled analysis of 2 placebo-controlled trials of etoricoxib.

Jensen MP, Schnitzer TJ, Wang H, Smugar SS, Peloso PM, Gammaitoni A.

Clin J Pain. 2012 Jan;28(1):1-7. doi: 10.1097/AJP.0b013e3182236209.


Intermittent or daily montelukast versus placebo for episodic asthma in children.

Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, Reiss TF, Philip G, Gurner DM.

Ann Allergy Asthma Immunol. 2011 Jun;106(6):518-26. doi: 10.1016/j.anai.2011.01.017. Epub 2011 Mar 4.


The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma.

Philip G, Villarán C, Shah SR, Vandormael K, Smugar SS, Reiss TF.

J Asthma. 2011 Jun;48(5):495-502. doi: 10.3109/02770903.2011.573042. Epub 2011 May 5.


Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.

Bingham CO 3rd, Smugar SS, Wang H, Peloso PM, Gammaitoni A.

Pain Med. 2011 Mar;12(3):352-61. doi: 10.1111/j.1526-4637.2011.01060.x. Epub 2011 Feb 18.


MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.

Bernstein JA, Liu N, Knorr BA, Smugar SS, Hanley WD, Reiss TF, Greenberg S.

Respir Med. 2011 Mar;105(3):392-401. doi: 10.1016/j.rmed.2010.09.021. Epub 2010 Nov 13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk